开发和制造高价值肺炎球菌多糖合物疫苗的当前趋势及其挑战
Shital S Jain1, Vikas K Singh2, Rajesh Kumar Kante2
1Savitribai Phule Pune University, Department of Biotechnology, Pune, Maharashtra, 411007, India; Serum Institute of India Pvt. Ltd., Hadapsar, Pune, Maharashtra, 411028, India.
概括
开发高性肺炎球菌合疫苗 (PCVs) 对于更广泛地保护人们免受Streptococcus pneumoniae的侵害至关重要. 制造复杂性,稳定性和成本仍然是全球疫苗覆盖范围更广泛的关键挑战.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 疫苗开发 疫苗开发
背景情况:
- 肺炎球菌结合疫苗 (PCV) 保护肺炎球菌,这是传染病的主要原因.
- 目前的PCV覆盖了有限的血清型,需要开发更高价值的疫苗来解决血清型替代和抗生素耐药性的问题.
- 对于婴儿,成年人,老年人和免疫力低下的人来说,需要更高价值的PCV.
研究的目的:
- 审查高价值肺炎球菌联合疫苗 (PCV) 的现有和新兴制造工艺.
- 确定和讨论与开发和生产高价值PCVs相关的挑战.
- 突出改善PCV配方的需要,以加强对肺炎球菌疾病的全球保护.
主要方法:
- 关于制造肺炎球菌联合疫苗的科学文献的综述.
- 对多糖体净化,修饰和结合的不同方法的分析.
- 检查高价值结合物的稳定性和免疫性方面的挑战.
主要成果:
- 目前正在探索使用各种S. pneumoniae血清型和载体蛋白质的高价值PCV的多种制造工艺.
- 关键的挑战包括复杂的多糖处理,合效率,合稳定性和疫苗免疫性.
- 目前,高成本和有限的供应阻碍了先进PCV的全球覆盖.
结论:
- 制造工艺的进步对于开发有效的高性肺炎球菌联合疫苗至关重要.
- 克服制造复杂性和成本障碍对于增加全球获得更广泛的肺炎球菌保护至关重要.
- 需要进一步研究新的结合策略和可扩展的生产,以满足下一代PCV的需求.
更多相关视频
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
3.4K
14:37High-throughput Synthesis of Carbohydrates and Functionalization of Polyanhydride Nanoparticles
Published on: July 6, 2012
11.4K
相关概念视频
Conjugated Proteins
18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Vaccinations
44.3K
Overview
44.3K
